Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. Nov 16, 2021; 9(32): 9917-9925
Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9917
Table 1 Long-term survival of cases with synchronous Virchow lymph node metastasis of colorectal cancer
No.
Ref.
Year
Age/gender
Primary location
Metastasis of another organ
Resection of Virchow LN
Postoperative chemotherapy
Disease free survival time
Overall survival time
1Watanabe et al[3]200973/MaleCecumParaaortic lymph nodes; Lung-5-fluorouracil, Leucovorin, FOLFOX, FOLFIRI-3 yr
2Hirose et al[4]201057/MaleRectum--FOLFOX, FOLFIRI-3 yr
3Ando et al[5]201363/MaleSigmoid colon--FOLFOX, FOLFIRI-5 yr
4Suliman et al[6]201954/MaleTransverse colon-+FOLFOX, FOLFIRI--
5Our case202056/MaleSigmoid colon-+FOLFOX, capecitabine, cetuximabSo farSo far
Table 2 Information from this case report organized into a timeline
Time lane
Events
June 3, 2020The male presented with a left cervical mass for one month
June 9, 2020Lymph node biopsy was performed and histopathological examination revealed that the metastatic adenocarcinoma was found in the tissue
June 18, 2020The patient underwent gastroenteroscopy and the results revealed that one pedunculated polyp with mucosal erosion was observed in sigmoid colon, and histological examination revealed that adenocarcinoma was found in the intramucosal tissue
June 30, 2020 to September 30, 2020Undergoing 6 cycles of chemotherapy with FOLFOX + cetuximab regimen
October 22, 2020The resection of sigmoid carcinoma and mesenteric lymph node dissection were performed. Histological examination showed moderately differentiated adenocarcinoma localized in the mucosa, and one of five paracolic lymph nodes contained metastatic carcinoma (ypT1N1M1)
November 30, 2020 to January 30, 2021Undergoing 4 cycles of chemotherapy with FOLFOX + capecitabine regimen
February 24, 2021Virchow lymph node dissection was selected by mutual consultation between the patient and us
February 25, 2021 to March 5, 2021Postoperative lymphatic leakage
March 24, 2021-So farThe patient received chemotherapy with capecitabine and cetuximab. At nearly half of a year following the surgery, the patient was asymptomatic, and there were no signs of tumor recurrence or progression